Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety
and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nasser Hanna, M.D.
Collaborators:
Amgen Bayer Onyx Pharmaceuticals Walther Cancer Institute